Surefire will now market the Surefire Precision 021, Surefire Infusion System mT/LT, and Surefire Guiding Catheters in Mexico
Achievement
Clinical Data Shows Surefire Technology Achieved 79% Objective Response versus 37% Using a Standard Microcatheter in Treating Primary Liver Cancer. Study presented at SIR 2017
Product
The New Flexion Guiding Catheter Includes a Nitinol Tip for Better Shape Retention and Improved Back-up Support
Achievement
Multiple clinical studies verify significantly better liver cancer outcomes with use of unique expandable tip infusion systems